Paper2199402
A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study.
Trump DL and 6 others. Invest New Drugs, 1990. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Papers, record 2199402. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2199402
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Organoplatinum Compounds | Major topic |
| Prostatic Neoplasms | Major topic |
| Bone Neoplasms | |
| Carboplatin | |
| Drug Evaluation | |
| Humans | |
| Male | |
| Pilot Projects |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA 21115 | NCI NIH HHS | United States | R10CA021115 | PubMed and NIH | NIH RePORTER |
| U10CA021115 | NIH | NIH RePORTER |
References9
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 442343 | Treatment of estrogen-resistant stage D carcinoma of prostate with cis diamminedichloroplatinum. | Urology | 1979 | https://conductscience.org/library/papers/442343 | PubMed |
| 2 | 6422006 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. | J Clin Oncol | 1983 | https://conductscience.org/library/papers/6422006 | PubMed |
| 3 | 6374169 | Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma. | J Urol | 1984 | https://conductscience.org/library/papers/6374169 | PubMed |
| 4 | 7194733 | Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. | Cancer | 1981 | https://conductscience.org/library/papers/7194733 | PubMed |
| 5 | 498150 | Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/498150 | PubMed |
| 6 | 498029 | A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. | Cancer | 1979 | https://conductscience.org/library/papers/498029 | PubMed |
| 7 | 6340081 | A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. | Prostate | 1983 | https://conductscience.org/library/papers/6340081 | PubMed |
| 8 | 765499 | Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma. | J Urol | 1976 | https://conductscience.org/library/papers/765499 | PubMed |
| 9 | 3894584 | Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? | J Clin Oncol | 1985 | https://conductscience.org/library/papers/3894584 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34631559 | A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss. | Front Oncol | 2021 | https://conductscience.org/library/papers/34631559 | PubMed |
| 29063869 | Role of chemotherapy in prostate cancer. | Asian J Androl | 2018 | https://conductscience.org/library/papers/29063869 | PubMed |
| 25755690 | Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC). | Int J Clin Exp Pathol | 2015 | https://conductscience.org/library/papers/25755690 | PubMed |
| 8738624 | Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer. | Int Urol Nephrol | 1996 | https://conductscience.org/library/papers/8738624 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2199402
GET https://conductscience.org/api/papers/v1/2199402/authors